Get started
Author

Matthew Bonderud

Institution: Zymeworks (Canada)
Observed institution: Zymeworks (Canada)
ORCID: 0009-0005-1424-7295
Observed ORCID: 0009-0005-1424-7295
OpenAlex ID: A5117230793
ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al. · Clinical Cancer Research · 1
Supplementary Figure S1 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S3 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Data from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S10 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S2 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S7 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S12 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S9 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Table T3 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S6 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S13 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S4 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Table T1 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Table T2 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S8 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S11 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S5 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Abstract 5640: ZW439, a novel CLDN18.2-targeting pan-RAS inhibitor antibody drug conjugate for the treatment of RAS mutated pancreatic cancer
2026 · Sam Lawn, Andrea Hernández Rojas, et al. · Cancer Research
Abstract 1686: Development of ZW418, a biparatopic PTK7-targeting antibody-drug conjugate incorporating a novel pan-RAS inhibitor payload for the treatment of non-small cell lung cancer
2026 · Luying Yang, Alex Wu, et al. · Cancer Research
Abstract 4431: ZW427, a Ly6E-targeting antibody drug conjugate bearing a novel pan-RAS inhibitor payload for the treatment of RAS mutated cancers
2026 · Dunja Urosev, Vidhi Khanna, et al. · Cancer Research
Abstract 1565: Design and development of biparatopic antibody-drug conjugates against protein tyrosine kinase 7
2025 · Luying Yang, Vincent Fung, et al. · Cancer Research
Works count: 22
Citation count: 1
H-index: 1
I10-index:
Year
Topic
Type